WallStreetZenWallStreetZen

NASDAQ: OGI
Organigram Global Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their OGI stock forecasts and price targets.

Forecast return on equity

Is OGI forecast to generate an efficient return?

Company
5.28%
Industry
30.74%
Market
90.47%
OGI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OGI forecast to generate an efficient return on assets?

Company
3.83%
Industry
15.4%
OGI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OGI earnings per share forecast

What is OGI's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.07+70.47%
Avg 2 year Forecast
$0.00-100%
Avg 3 year Forecast
$0.08+86.05%
OGI's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

OGI revenue forecast

What is OGI's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$170.6M+26.54%
Avg 2 year Forecast
$195.3M+44.91%
Avg 3 year Forecast
$234.4M+73.88%
OGI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OGI earnings growth forecast

How is OGI forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-20.02%
Industry
25.78%
Market
15.33%
OGI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
OGI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
OGI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

OGI revenue growth forecast

How is OGI forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
10.86%
Industry
4.14%
Market
9.68%
OGI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OGI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OGI vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
OGI$1.40N/AN/A
BIOA$4.52$5.00+10.62%Sell
DERM$6.78N/AN/A
ESPR$1.17$6.50+455.56%Buy
LFCR$6.73$6.00-10.85%Hold
View Top Pharmaceutical Stocks

Organigram Global Stock Forecast FAQ

What is OGI's earnings growth forecast for 2025-2027?

(NASDAQ: OGI) Organigram Global's forecast annual earnings growth rate of -20.02% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 25.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Organigram Global's earnings in 2025 is $12,192,142.On average, 3 Wall Street analysts forecast OGI's earnings for 2025 to be $9,810,176, with the lowest OGI earnings forecast at $8,030,158, and the highest OGI earnings forecast at $12,045,237. On average, 3 Wall Street analysts forecast OGI's earnings for 2026 to be $0, with the lowest OGI earnings forecast at -$1,338,360, and the highest OGI earnings forecast at $1,338,360.

In 2027, OGI is forecast to generate $10,706,877 in earnings, with the lowest earnings forecast at $10,706,877 and the highest earnings forecast at $10,706,877.

If you're new to stock investing, here's how to buy Organigram Global stock.

What is OGI's revenue growth forecast for 2025-2027?

(NASDAQ: OGI) Organigram Global's forecast annual revenue growth rate of 10.86% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Organigram Global's revenue in 2025 is $138,634,285.On average, 3 Wall Street analysts forecast OGI's revenue for 2025 to be $22,826,526,505, with the lowest OGI revenue forecast at $21,467,288,465, and the highest OGI revenue forecast at $23,936,561,983. On average, 3 Wall Street analysts forecast OGI's revenue for 2026 to be $26,139,903,441, with the lowest OGI revenue forecast at $23,773,282,108, and the highest OGI revenue forecast at $27,944,949,074.

In 2027, OGI is forecast to generate $31,365,796,289 in revenue, with the lowest revenue forecast at $31,365,796,289 and the highest revenue forecast at $31,365,796,289.

What is OGI's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: OGI) forecast ROA is 3.83%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.4%.

What is OGI's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: OGI) Organigram Global's current Earnings Per Share (EPS) is $0.04. On average, analysts forecast that OGI's EPS will be $0.07 for 2025, with the lowest EPS forecast at $0.06, and the highest EPS forecast at $0.09. On average, analysts forecast that OGI's EPS will be $0.00 for 2026, with the lowest EPS forecast at -$0.01, and the highest EPS forecast at $0.01. In 2027, OGI's EPS is forecast to hit $0.08 (min: $0.08, max: $0.08).

What is OGI's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: OGI) forecast ROE is 5.28%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.